

CME Lunch Symposium

SATURDAY, SEPTEMBER 10

11:40 AM - 12:30 PM

Optimizing Lipid Lowering Therapy in Women: Gaps Perspectives and Advances



This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress.

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

PROGRAM OVERVIEW:

Atherosclerotic cardiovascular disease (ASCVD) events are among the leading causes of death in women in the US and globally. Even with advances in LDL-C (low-density lipoprotein cholesterol) lowering therapy, LDL-C goal achievement in high-risk women is lower than that in men, with clinical inertia, statin intolerance, and non-adherence being major factors for continued ASCVD residual risk. The landscape of LDL-C lowering therapy is rapidly evolving, with several new and emerging agents that may help address these gaps, and now the options for combination therapy go beyond what is in the guidelines. During this symposium, faculty will discuss and offer their perspectives on how to optimize and integrate these agents into standard of care, and optimize LDL-C lowering therapy in women.

LEARNING OBJECTIVES:

After completing this activity, the participant should be better able to:

- Recognize the burden of ASCVD risk in women, and challenges with optimizing statin therapy
- Explain the need for the early and adequate intensification of LDL-C lowering therapy beyond statins in women to address ASCVD risk.
- Summarize the efficacy and safety of PCSK9 inhibitors across trial and real-world studies
- Discuss the rationale, efficacy, and safety of novel LDL-C lowering agents and their potential impact in addressing current gaps in lipid-lowering therapy in women.
- Select individualized treatment strategies to optimize lipid-lowering therapy in women that prioritize the early initiation and intensification of therapy to reduce ASCVD risk.

Optimizing Lipid Lowering Therapy in Women:
Gaps Perspectives and Advances

FACULTY CHAIR



Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC


Director of Women's Cardiovascular Health
Associate Professor of Medicine
Johns Hopkins Medicine
Baltimore, MD

FACULTY CHAIR



Christie M. Ballantyne, MD

Professor of Medicine, Baylor College of Medicine
Houston, TX



Heather M. Johnson, MD, MS, MMM, FAHA, FACC, FASPC

Preventive Cardiologist/Cardiologist, Lynn Women's Health & Wellness Institute/Baptist Health
South Florida
Boca Raton, FL



Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC

Director, Preventive Cardiology Associate Director, Barbra Streisand Women's Heart Center,
Cedars- Sinai Heart Institute
Los Angeles, CA

Optimizing Lipid Lowering Therapy in Women: Gaps Perspectives and Advances

JOINT PROVIDERSHIP STATEMENT



In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION

PACE designates this live activity for a maximum of 0.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

PHARMACY CONTINUING EDUCATION

PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-22-178-L01-P. Type of activity: Knowledge

HOW TO REQUEST CE CREDIT

An evaluation link will be provided post-meeting to all attendees of the Masterclass. Several email reminders will be sent post-meeting. **Please claim your CE credits by completing the evaluation by Friday, September 30, 2022.**

Upon completion of the CME/CE evaluation, attendees can download their general sessions certificate. For satellite symposia, certificates will be provided separately via email within 5-7 business days after the September 30 deadline.

For Pharmacists: Pharmacists have until the September 30 deadline to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required. Expect credit uploads to be completed within 5-7 business days after the evaluation deadline.

For questions regarding the evaluation, please contact: cmhc_eval@cardiometabolicealth.org

DISCLOSURES

Information on planner and faculty disclosure is available by following [this link](#).

DISCLOSURE OF CONFLICT OF INTEREST

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Optimizing Lipid Lowering Therapy in Women: Gaps Perspectives and Advances

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.